JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gutiérrez-Puente, Y.
Right arrow Articles by Lopez-Berestein, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gutiérrez-Puente, Y.
Right arrow Articles by Lopez-Berestein, G.

Vol. 291, Issue 2, 865-869, November 1999

Safety, Pharmacokinetics, and Tissue Distribution of Liposomal P-Ethoxy Antisense Oligonucleotides Targeted to Bcl-21

Yolanda Gutiérrez-Puente2 4, Ana M. Tari2, Clifton Stephens3, Michael Rosenblum2, Reyes Tamez Guerra4 and Gabriel Lopez-Berestein2

Department of Bioimmunotherapy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas

Antisense oligonucleotides (oligos) have the ability to selectively block disease-causing genes, thereby inhibiting production of disease-associated proteins. However, their effectiveness has been limited by their low intracellular delivery. We had previously demonstrated that liposomes could increase the intracellular uptake of P-ethoxy oligos, hydrophobic analogs of phosphodiesters, and that liposomal Bcl-2 P-ethoxy antisense oligos (L-Bcl-2) could selectively inhibit Bcl-2 protein production, thereby inducing growth inhibition in Follicular Lymphoma cell lines. To understand the in vivo behavior of L-Bcl-2, we conducted a series of studies to evaluate the safety, pharmacokinetics, and tissue distribution of i.v. injections of L-Bcl-2 in normal rodents. Daily administration of 20 mg of L-Bcl-2/kg of body weight in 5 consecutive days had no adverse effects on renal or hepatic functions, nor on hematological parameters. Histopathology also did not reveal any significant changes in the morphology of the organs studied. In rats, the area under the curve of L-Bcl-2 reflects a two-compartment model of distribution with a biphasic plasma clearance. The T1/2alpha and T1/2beta were approximately 8 min and 4.2 h, respectively, and the Vd was 79 ml, indicating a broad body distribution. The highest concentrations of L-Bcl-2 were found in spleen > liver > kidneys. These studies showed that in the schedules studied no significant toxicity associated with L-Bcl-2 was observed over 6 weeks, and that L-Bcl-2 could be widely distributed in the body.

0022-3565/99/2912-0865$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Cancer Res.Home page
G. J. Villares, M. Zigler, H. Wang, V. O. Melnikova, H. Wu, R. Friedman, M. C. Leslie, P. E. Vivas-Mejia, G. Lopez-Berestein, A. K. Sood, et al.
Targeting Melanoma Growth and Metastasis with Systemic Delivery of Liposome-Incorporated Protease-Activated Receptor-1 Small Interfering RNA
Cancer Res., November 1, 2008; 68(21): 9078 - 9086.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. Hussain, A. Pluckthun, T. M. Allen, and U. Zangemeister-Wittke
Chemosensitization of carcinoma cells using epithelial cell adhesion molecule-targeted liposomal antisense against bcl-2/bcl-xL
Mol. Cancer Ther., December 1, 2006; 5(12): 3170 - 3180.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Halder, A. A. Kamat, C. N. Landen Jr., L. Y. Han, S. K. Lutgendorf, Y. G. Lin, W. M. Merritt, N. B. Jennings, A. Chavez-Reyes, R. L. Coleman, et al.
Focal Adhesion Kinase Targeting Using In vivo Short Interfering RNA Delivery in Neutral Liposomes for Ovarian Carcinoma Therapy.
Clin. Cancer Res., August 15, 2006; 12(16): 4916 - 4924.
[Abstract] [Full Text] [PDF]

Home page
 aacredbookHome page
A. K. Sood, C. N. Landen, A. Sanguino, and G. Lopez-Berestein
Therapeutic gene silencing in vivo using RNA interference
Am. Assoc. Cancer Res. Educ. Book, April 1, 2006; 2006(1): 353 - 358.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
C. N. Landen Jr., A. Chavez-Reyes, C. Bucana, R. Schmandt, M. T. Deavers, G. Lopez-Berestein, and A. K. Sood
Therapeutic EphA2 Gene Targeting In vivo Using Neutral Liposomal Small Interfering RNA Delivery
Cancer Res., August 1, 2005; 65(15): 6910 - 6918.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
C. Brignole, F. Pastorino, D. Marimpietri, G. Pagnan, A. Pistorio, T. M. Allen, V. Pistoia, and M. Ponzoni
Immune Cell-Mediated Antitumor Activities of GD2-Targeted Liposomal c-myb Antisense Oligonucleotides Containing CpG Motifs
J Natl Cancer Inst, August 4, 2004; 96(15): 1171 - 1180.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. Pastorino, C. Brignole, D. Marimpietri, G. Pagnan, A. Morando, D. Ribatti, S. C. Semple, C. Gambini, T. M. Allen, and M. Ponzoni
Targeted Liposomal c-myc Antisense Oligodeoxynucleotides Induce Apoptosis and Inhibit Tumor Growth and Metastases in Human Melanoma Models
Clin. Cancer Res., October 1, 2003; 9(12): 4595 - 4605.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1999 by the American Society for Pharmacology and Experimental Therapeutics.